ATNXQ Stock Analysis

Athenex Inc - Real-time stock metrics, market data, and comprehensive analysis

Loading...

Fetching stock data...

Athenex Inc

Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments.

Market Data

Current Price

$0.02

+$0.00 (0.00%)
Market Cap

-

Total Company Value
Day Range
$0.02 - $0.02
Session Volume
3.59K
Shares traded today

Valuation Metrics

P/E Ratio

-

Price ÷ Earnings
EPS (Basic)

-

Earnings Per Share
Price-to-Book

-

Market Value ÷ Book Value

Financial Health

Revenue (TTM)

-

Trailing 12 Months
Net Income (TTM)

-

Profit After Tax
Gross Margin

-

Revenue Efficiency

Returns & Dividends

Dividend Yield

-

Annual Dividend ÷ Price
Annual Dividend

-

Per Share
Payout Ratio

-

Dividend ÷ EPS

Price Performance

Price Chart
All times are in Eastern Time (ET)

Recent News

No news available

Data Source: Financial data is sourced from SEC filings via Tiingo and may be delayed. Market Status: OPEN - Prices update every 2 minutes. (Last updated: 2:11 PM)
Logos provided by Logo.dev

Contact Me

Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.